25 XP   0   0   10

Hunan Jingfeng Pharmaceutical
Buy, Hold or Sell?

Let's analyse Hunan Jingfeng Pharmaceutical together

PenkeI guess you are interested in Hunan Jingfeng Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hunan Jingfeng Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Hunan Jingfeng Pharmaceutical

I send you an email if I find something interesting about Hunan Jingfeng Pharmaceutical.

Quick analysis of Hunan Jingfeng Pharmaceutical (30 sec.)










What can you expect buying and holding a share of Hunan Jingfeng Pharmaceutical? (30 sec.)

How much money do you get?

How much money do you get?
¥0.00
When do you have the money?
1 year
How often do you get paid?
92.5%

What is your share worth?

Current worth
¥-0.17
Expected worth in 1 year
¥-0.59
How sure are you?
65.0%

+ What do you gain per year?

Total Gains per Share
¥-0.40
Return On Investment
-49.5%

For what price can you sell your share?

Current Price per Share
¥0.80
Expected price per share
¥0 - ¥1.51
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Hunan Jingfeng Pharmaceutical (5 min.)




Live pricePrice per Share (EOD)

¥0.80

Intrinsic Value Per Share

¥-5.23 - ¥-6.32

Total Value Per Share

¥-5.40 - ¥-6.49

2. Growth of Hunan Jingfeng Pharmaceutical (5 min.)




Is Hunan Jingfeng Pharmaceutical growing?

Current yearPrevious yearGrowGrow %
How rich?-$20.4m$38m-$34.3m-938.0%

How much money is Hunan Jingfeng Pharmaceutical making?

Current yearPrevious yearGrowGrow %
Making money-$7.3m-$4.4m-$2.8m-38.8%
Net Profit Margin-47.7%-14.4%--

How much money comes from the company's main activities?

3. Financial Health of Hunan Jingfeng Pharmaceutical (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Hunan Jingfeng Pharmaceutical? (5 min.)

Welcome investor! Hunan Jingfeng Pharmaceutical's management wants to use your money to grow the business. In return you get a share of Hunan Jingfeng Pharmaceutical.

What can you expect buying and holding a share of Hunan Jingfeng Pharmaceutical?

First you should know what it really means to hold a share of Hunan Jingfeng Pharmaceutical. And how you can make/lose money.

Speculation

The Price per Share of Hunan Jingfeng Pharmaceutical is ¥0.8. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hunan Jingfeng Pharmaceutical.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hunan Jingfeng Pharmaceutical, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥-0.17. Based on the TTM, the Book Value Change Per Share is ¥-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hunan Jingfeng Pharmaceutical.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.000.1%-0.01-1.0%-0.01-0.6%-0.02-2.3%0.00-0.6%
Usd Book Value Change Per Share0.000.1%-0.01-1.8%0.00-0.6%-0.02-2.9%0.00-0.1%
Usd Dividend Per Share0.000.1%0.000.1%0.000.2%0.000.3%0.000.5%
Usd Total Gains Per Share0.000.2%-0.01-1.7%0.00-0.4%-0.02-2.6%0.000.5%
Usd Price Per Share0.35-0.39-0.44-0.53-0.99-
Price to Earnings Ratio158.12-20.37-105.08-69.55-55.72-
Price-to-Total Gains Ratio250.87-487.32-32.71-184.84--47.00-
Price to Book Ratio-14.91--2.31-10.62-4.53--47.32-
Price-to-Total Gains Ratio250.87-487.32-32.71-184.84--47.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.11008
Number of shares9084
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.01-0.02
Usd Total Gains Per Share-0.01-0.02
Gains per Quarter (9084 shares)-123.74-191.32
Gains per Year (9084 shares)-494.96-765.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
133-528-50591-857-775
266-1056-1000183-1714-1540
399-1584-1495274-2570-2305
4132-2112-1990366-3427-3070
5165-2640-2485457-4284-3835
6198-3168-2980549-5141-4600
7231-3696-3475640-5997-5365
8264-4224-3970732-6854-6130
9297-4752-4465823-7711-6895
10330-5280-4960915-8568-7660

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%26.012.02.065.0%51.012.025.058.0%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%23.017.00.057.5%44.044.00.050.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%37.00.03.092.5%71.00.017.080.7%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%10.010.00.050.0%26.014.00.065.0%55.033.00.062.5%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Hunan Jingfeng Pharmaceutical

About Hunan Jingfeng Pharmaceutical

Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. In addition, the company provides CDMO/CMO services. The company was founded in 2003 and is headquartered in Shanghai, China.

Fundamental data was last updated by Penke on 2024-06-20 07:47:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is overpriced.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Hunan Jingfeng Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hunan Jingfeng Pharmaceutical earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Hunan Jingfeng Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 3.5% means that ¥0.03 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 3.5%. The company is making a profit. +1
  • The TTM is -47.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ3.5%TTM-47.7%+51.2%
TTM-47.7%YOY-14.4%-33.3%
TTM-47.7%5Y62.1%-109.8%
5Y62.1%10Y35.5%+26.6%
1.1.2. Return on Assets

Shows how efficient Hunan Jingfeng Pharmaceutical is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hunan Jingfeng Pharmaceutical to the Drug Manufacturers - General industry mean.
  • 0.3% Return on Assets means that Hunan Jingfeng Pharmaceutical generated ¥0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -4.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.3%TTM-4.8%+5.1%
TTM-4.8%YOY-2.2%-2.6%
TTM-4.8%5Y-4.7%-0.1%
5Y-4.7%10Y-1.6%-3.1%
1.1.3. Return on Equity

Shows how efficient Hunan Jingfeng Pharmaceutical is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hunan Jingfeng Pharmaceutical to the Drug Manufacturers - General industry mean.
  • 0.0% Return on Equity means Hunan Jingfeng Pharmaceutical generated ¥0.00 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-6.5%+6.5%
TTM-6.5%YOY-16.6%+10.0%
TTM-6.5%5Y-21.6%+15.1%
5Y-21.6%10Y-9.4%-12.2%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Hunan Jingfeng Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hunan Jingfeng Pharmaceutical is operating .

  • Measures how much profit Hunan Jingfeng Pharmaceutical makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hunan Jingfeng Pharmaceutical to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.6%-0.6%
TTM0.6%YOY1.1%-0.5%
TTM0.6%5Y38.6%-38.0%
5Y38.6%10Y20.4%+18.2%
1.2.2. Operating Ratio

Measures how efficient Hunan Jingfeng Pharmaceutical is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.25 means that the operating costs are ¥1.25 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 1.247. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.551. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.247TTM1.551-0.305
TTM1.551YOY1.229+0.322
TTM1.5515Y1.039+0.512
5Y1.03910Y0.755+0.284
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Hunan Jingfeng Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hunan Jingfeng Pharmaceutical is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.24 means the company has ¥0.24 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 0.240. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.367. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.240TTM0.367-0.127
TTM0.367YOY0.530-0.163
TTM0.3675Y0.724-0.357
5Y0.72410Y0.582+0.141
1.3.2. Quick Ratio

Measures if Hunan Jingfeng Pharmaceutical is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hunan Jingfeng Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.09 means the company can pay off ¥0.09 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 0.085. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.156. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.085TTM0.156-0.070
TTM0.156YOY0.212-0.056
TTM0.1565Y0.314-0.159
5Y0.31410Y0.685-0.371
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Hunan Jingfeng Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hunan Jingfeng Pharmaceutical assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hunan Jingfeng Pharmaceutical to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 1.14 means that Hunan Jingfeng Pharmaceutical assets are financed with 113.5% credit (debt) and the remaining percentage (100% - 113.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 1.135. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.000. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.135TTM1.000+0.136
TTM1.000YOY0.825+0.175
TTM1.0005Y0.752+0.247
5Y0.75210Y0.620+0.132
1.4.2. Debt to Equity Ratio

Measures if Hunan Jingfeng Pharmaceutical is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hunan Jingfeng Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 0.0% means that company has ¥0.00 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.286-4.286
TTM4.286YOY5.821-1.535
TTM4.2865Y3.628+0.658
5Y3.62810Y5.833-2.205
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Hunan Jingfeng Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Hunan Jingfeng Pharmaceutical generates.

  • Above 15 is considered overpriced but always compare Hunan Jingfeng Pharmaceutical to the Drug Manufacturers - General industry mean.
  • A PE ratio of 158.12 means the investor is paying ¥158.12 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The EOD is 50.197. Based on the earnings, the company is expensive. -2
  • The MRQ is 158.120. Based on the earnings, the company is expensive. -2
  • The TTM is 20.368. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD50.197MRQ158.120-107.923
MRQ158.120TTM20.368+137.752
TTM20.368YOY105.082-84.714
TTM20.3685Y69.549-49.182
5Y69.54910Y55.717+13.833
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The EOD is 21.839. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 68.794. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 58.791. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD21.839MRQ68.794-46.955
MRQ68.794TTM58.791+10.003
TTM58.791YOY187.007-128.217
TTM58.7915Y77.523-18.732
5Y77.52310Y41.426+36.097
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hunan Jingfeng Pharmaceutical is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of -14.91 means the investor is paying ¥-14.91 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Hunan Jingfeng Pharmaceutical:

  • The EOD is -4.735. Based on the equity, the company is expensive. -2
  • The MRQ is -14.915. Based on the equity, the company is expensive. -2
  • The TTM is -2.310. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.735MRQ-14.915+10.180
MRQ-14.915TTM-2.310-12.605
TTM-2.310YOY10.622-12.933
TTM-2.3105Y4.528-6.838
5Y4.52810Y-47.319+51.848
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hunan Jingfeng Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.006-0.106+1946%-0.033+681%-0.171+3095%-0.004+173%
Book Value Per Share---0.1690.030-658%0.314-154%1.009-117%1.737-110%
Current Ratio--0.2400.367-35%0.530-55%0.724-67%0.582-59%
Debt To Asset Ratio--1.1351.000+14%0.825+38%0.752+51%0.620+83%
Debt To Equity Ratio---4.286-100%5.821-100%3.628-100%5.833-100%
Dividend Per Share--0.0040.007-35%0.010-58%0.018-76%0.032-86%
Eps--0.004-0.060+1609%-0.037+1029%-0.135+3486%-0.035+988%
Free Cash Flow Per Share--0.0090.007+33%0.033-72%-0.005+151%-0.027+394%
Free Cash Flow To Equity Per Share--0.0090.000+102%-0.035+485%-0.077+939%0.087-89%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.950+5%
Intrinsic Value_10Y_max---6.325--------
Intrinsic Value_10Y_min---5.233--------
Intrinsic Value_1Y_max---0.055--------
Intrinsic Value_1Y_min---0.053--------
Intrinsic Value_3Y_max---0.605--------
Intrinsic Value_3Y_min---0.569--------
Intrinsic Value_5Y_max---1.688--------
Intrinsic Value_5Y_min---1.529--------
Market Cap703819212.800-215%2217031364.5202487561977.453-11%2830673974.343-22%3368803679.286-34%6356335733.856-65%
Net Profit Margin--0.035-0.477+1469%-0.144+514%0.621-94%0.355-90%
Operating Margin---0.006-100%0.011-100%0.386-100%0.204-100%
Operating Ratio--1.2471.551-20%1.229+1%1.039+20%0.755+65%
Pb Ratio-4.735+68%-14.915-2.310-85%10.622-240%4.528-429%-47.319+217%
Pe Ratio50.197-215%158.12020.368+676%105.082+50%69.549+127%55.717+184%
Price Per Share0.800-215%2.5202.828-11%3.218-22%3.829-34%7.225-65%
Price To Free Cash Flow Ratio21.839-215%68.79458.791+17%187.007-63%77.523-11%41.426+66%
Price To Total Gains Ratio79.641-215%250.870487.315-49%32.711+667%184.840+36%-47.001+119%
Quick Ratio--0.0850.156-45%0.212-60%0.314-73%0.685-88%
Return On Assets--0.003-0.048+1604%-0.022+776%-0.047+1573%-0.016+601%
Return On Equity----0.0650%-0.1660%-0.2160%-0.0940%
Total Gains Per Share--0.010-0.099+1086%-0.023+327%-0.153+1624%0.028-64%
Usd Book Value---20453793.9533663742.017-658%38029499.098-154%122166587.710-117%210274403.089-110%
Usd Book Value Change Per Share--0.001-0.015+1946%-0.005+681%-0.024+3095%-0.001+173%
Usd Book Value Per Share---0.0230.004-658%0.043-154%0.139-117%0.239-110%
Usd Dividend Per Share--0.0010.001-35%0.001-58%0.003-76%0.004-86%
Usd Eps--0.001-0.008+1609%-0.005+1029%-0.019+3486%-0.005+988%
Usd Free Cash Flow--1108614.140835397.501+33%3985005.113-72%-570128.117+151%-2684940.532+342%
Usd Free Cash Flow Per Share--0.0010.001+33%0.005-72%-0.001+151%-0.004+394%
Usd Free Cash Flow To Equity Per Share--0.0010.000+102%-0.005+485%-0.011+939%0.012-89%
Usd Market Cap96845523.681-215%305063515.758342288528.097-11%389500738.870-22%463547386.270-34%874631796.979-65%
Usd Price Per Share0.110-215%0.3470.389-11%0.443-22%0.527-34%0.994-65%
Usd Profit--482328.386-7324359.031+1619%-4479647.144+1029%-16342664.495+3488%-4288463.266+989%
Usd Revenue--13839216.63520000621.307-31%28734678.024-52%29836030.669-54%53826642.161-74%
Usd Total Gains Per Share--0.001-0.014+1086%-0.003+327%-0.021+1624%0.004-64%
 EOD+3 -5MRQTTM+18 -16YOY+16 -185Y+18 -1610Y+13 -22

3.2. Fundamental Score

Let's check the fundamental score of Hunan Jingfeng Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1550.197
Price to Book Ratio (EOD)Between0-1-4.735
Net Profit Margin (MRQ)Greater than00.035
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.085
Current Ratio (MRQ)Greater than10.240
Debt to Asset Ratio (MRQ)Less than11.135
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.003
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Hunan Jingfeng Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5018.062
Ma 20Greater thanMa 501.230
Ma 50Greater thanMa 1001.533
Ma 100Greater thanMa 2001.889
OpenGreater thanClose0.800
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-03-312023-06-302023-09-302023-12-312024-03-31
Interest Income  2255918168701,6866172,303-2,410-108



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets1,099,909
Total Liabilities1,248,555
Total Stockholder Equity-45,972
 As reported
Total Liabilities 1,248,555
Total Stockholder Equity+ -45,972
Total Assets = 1,099,909

Assets

Total Assets1,099,909
Total Current Assets258,878
Long-term Assets841,031
Total Current Assets
Net Receivables 92,055
Inventory 63,623
Other Current Assets 15,663
Total Current Assets  (as reported)258,878
Total Current Assets  (calculated)171,341
+/- 87,537
Long-term Assets
Property Plant Equipment 424,262
Goodwill 117
Intangible Assets 168,911
Long-term Assets Other 189,390
Long-term Assets  (as reported)841,031
Long-term Assets  (calculated)782,680
+/- 58,351

Liabilities & Shareholders' Equity

Total Current Liabilities1,078,000
Long-term Liabilities170,555
Total Stockholder Equity-45,972
Total Current Liabilities
Short Long Term Debt 194,523
Accounts payable 165,388
Other Current Liabilities 9,140
Total Current Liabilities  (as reported)1,078,000
Total Current Liabilities  (calculated)369,051
+/- 708,950
Long-term Liabilities
Long term Debt 72,185
Capital Lease Obligations Min Short Term Debt21,755
Long-term Liabilities Other 49,083
Long-term Liabilities  (as reported)170,555
Long-term Liabilities  (calculated)143,023
+/- 27,532
Total Stockholder Equity
Total Stockholder Equity (as reported)-45,972
Total Stockholder Equity (calculated)0
+/- 45,972
Other
Capital Stock416,690
Common Stock Shares Outstanding 879,774
Net Debt 266,708
Net Invested Capital 220,736
Net Working Capital -819,122
Property Plant and Equipment Gross 424,262



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-06-302000-12-312000-06-30
> Total Assets 
678,481
697,922
669,166
620,882
701,018
718,825
763,760
866,675
883,002
882,153
849,382
833,233
870,030
866,834
889,556
861,188
853,090
855,166
840,144
825,753
824,841
796,440
822,472
824,855
796,811
845,011
814,384
838,216
885,118
884,873
989,235
978,897
997,611
959,840
784,806
525,708
530,549
501,482
471,373
465,066
453,971
434,187
421,448
414,876
397,823
395,913
370,133
366,093
366,913
363,398
336,780
353,955
351,025
346,773
1,913,799
3,064,272
3,048,941
3,158,014
3,442,648
3,978,622
3,912,902
3,955,841
5,134,008
5,060,660
5,179,307
5,195,939
4,868,764
4,602,610
4,770,511
5,034,651
5,227,113
5,163,742
5,276,488
5,742,726
4,350,073
4,370,109
4,056,631
3,976,746
2,690,276
2,601,148
2,513,365
2,458,057
1,792,300
1,688,404
1,683,031
1,626,590
1,468,474
1,474,206
1,461,350
1,435,588
1,060,346
1,099,909
1,099,9091,060,3461,435,5881,461,3501,474,2061,468,4741,626,5901,683,0311,688,4041,792,3002,458,0572,513,3652,601,1482,690,2763,976,7464,056,6314,370,1094,350,0735,742,7265,276,4885,163,7425,227,1135,034,6514,770,5114,602,6104,868,7645,195,9395,179,3075,060,6605,134,0083,955,8413,912,9023,978,6223,442,6483,158,0143,048,9413,064,2721,913,799346,773351,025353,955336,780363,398366,913366,093370,133395,913397,823414,876421,448434,187453,971465,066471,373501,482530,549525,708784,806959,840997,611978,897989,235884,873885,118838,216814,384845,011796,811824,855822,472796,440824,841825,753840,144855,166853,090861,188889,556866,834870,030833,233849,382882,153883,002866,675763,760718,825701,018620,882669,166697,922678,481
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,356,736
2,542,951
2,590,364
2,467,825
2,527,993
2,881,982
1,783,644
1,798,731
1,541,636
1,556,284
1,021,877
959,574
883,694
853,790
677,509
653,191
647,962
599,882
571,297
557,692
553,259
547,808
213,757
258,878
258,878213,757547,808553,259557,692571,297599,882647,962653,191677,509853,790883,694959,5741,021,8771,556,2841,541,6361,798,7311,783,6442,881,9822,527,9932,467,8252,590,3642,542,9512,356,73600000000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
466,350
429,701
512,107
445,330
789,029
1,125,247
405,475
309,725
288,161
274,039
164,196
98,953
105,302
123,589
172,177
154,334
182,611
185,330
181,392
180,550
162,429
174,650
13,165
0
013,165174,650162,429180,550181,392185,330182,611154,334172,177123,589105,30298,953164,196274,039288,161309,725405,4751,125,247789,029445,330512,107429,701466,35000000000000000000000000000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,000
0
20,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000020,000020,00000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
131,782
142,273
101,670
98,682
115,777
117,123
144,327
122,009
0
121,045
150,946
132,528
138,794
142,818
348,464
338,442
342,829
354,084
351,477
338,271
224,429
199,831
251,153
214,733
265,174
244,812
240,533
256,706
297,339
278,518
136,220
144,724
161,778
148,413
119,280
133,275
134,067
123,932
117,126
113,640
108,290
102,317
97,027
93,030
106,290
100,121
94,227
82,318
92,431
89,016
88,789
80,907
82,005
91,914
670,649
639,424
765,058
939,156
1,085,932
1,137,073
1,133,758
1,116,264
1,558,035
1,752,073
1,401,930
1,524,344
1,536,174
1,417,040
1,293,159
1,439,619
1,590,348
776,041
722,789
715,031
824,779
917,851
875,606
1,015,328
539,310
532,253
484,427
439,174
293,082
268,797
279,077
234,470
224,183
214,882
251,947
246,752
77,482
92,055
92,05577,482246,752251,947214,882224,183234,470279,077268,797293,082439,174484,427532,253539,3101,015,328875,606917,851824,779715,031722,789776,0411,590,3481,439,6191,293,1591,417,0401,536,1741,524,3441,401,9301,752,0731,558,0351,116,2641,133,7581,137,0731,085,932939,156765,058639,424670,64991,91482,00580,90788,78989,01692,43182,31894,227100,121106,29093,03097,027102,317108,290113,640117,126123,932134,067133,275119,280148,413161,778144,724136,220278,518297,339256,706240,533244,812265,174214,733251,153199,831224,429338,271351,477354,084342,829338,442348,464142,818138,794132,528150,946121,0450122,009144,327117,123115,77798,682101,670142,273131,782
       Other Current Assets 
20,354
41,795
79,442
27,203
43,660
60,144
72,477
33,618
0
55,301
34,238
30,973
42,051
40,900
37,965
39,708
29,753
25,763
18,298
20,349
20,130
18,964
10,056
15,456
13,667
25,487
19,730
20,269
20,125
30,286
67,224
72,542
88,626
66,866
49,279
50,697
48,303
50,511
47,646
52,420
56,832
50,016
50,294
52,048
17,902
19,162
4,311
4,713
7,855
13,655
5,052
32,608
8,364
6,029
57,412
84,961
130,905
120,222
166,335
208,285
292,145
328,131
189,615
288,840
294,606
518,925
297,146
326,527
278,668
351,045
198,984
4,562
4,645
135,946
97,116
245,639
55,942
52,075
85,978
82,224
84,124
81,964
56,854
60,440
29,751
43,826
45,353
48,106
34,454
45,238
14,916
15,663
15,66314,91645,23834,45448,10645,35343,82629,75160,44056,85481,96484,12482,22485,97852,07555,942245,63997,116135,9464,6454,562198,984351,045278,668326,527297,146518,925294,606288,840189,615328,131292,145208,285166,335120,222130,90584,96157,4126,0298,36432,6085,05213,6557,8554,7134,31119,16217,90252,04850,29450,01656,83252,42047,64650,51148,30350,69749,27966,86688,62672,54267,22430,28620,12520,26919,73025,48713,66715,45610,05618,96420,13020,34918,29825,76329,75339,70837,96540,90042,05130,97334,23855,301033,61872,47760,14443,66027,20379,44241,79520,354
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,695,917
2,748,496
2,860,744
2,566,429
2,571,379
2,514,995
2,420,462
1,668,399
1,641,574
1,629,671
1,604,267
1,114,790
1,035,213
1,035,068
1,026,708
897,178
916,514
908,091
887,780
846,589
841,031
841,031846,589887,780908,091916,514897,1781,026,7081,035,0681,035,2131,114,7901,604,2671,629,6711,641,5741,668,3992,420,4622,514,9952,571,3792,566,4292,860,7442,748,4962,695,91700000000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
112,415
115,106
126,914
158,369
160,425
166,823
168,004
189,153
0
189,125
179,073
177,878
177,046
176,514
146,332
144,225
242,860
141,769
274,631
177,943
355,266
259,320
279,251
133,947
229,368
120,532
198,354
115,398
207,051
115,812
196,070
129,661
187,066
127,406
159,837
106,563
148,823
104,773
146,999
103,735
169,564
112,817
164,544
107,757
162,257
106,395
158,044
89,550
129,213
88,358
122,808
82,402
81,045
80,244
347,395
405,603
416,388
459,475
483,865
608,136
634,227
656,431
667,684
672,439
692,366
738,891
784,973
770,991
805,775
846,995
1,049,247
1,103,280
1,116,494
1,211,777
1,231,950
1,226,000
1,080,901
1,042,243
1,013,819
1,004,474
990,300
967,190
726,103
709,116
702,735
694,095
566,419
555,981
544,711
522,816
434,206
424,262
424,262434,206522,816544,711555,981566,419694,095702,735709,116726,103967,190990,3001,004,4741,013,8191,042,2431,080,9011,226,0001,231,9501,211,7771,116,4941,103,2801,049,247846,995805,775770,991784,973738,891692,366672,439667,684656,431634,227608,136483,865459,475416,388405,603347,39580,24481,04582,402122,80888,358129,21389,550158,044106,395162,257107,757164,544112,817169,564103,735146,999104,773148,823106,563159,837127,406187,066129,661196,070115,812207,051115,398198,354120,532229,368133,947279,251259,320355,266177,943274,631141,769242,860144,225146,332176,514177,046177,878179,073189,1250189,153168,004166,823160,425158,369126,914115,106112,415
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
355,941
684,042
687,850
687,416
688,348
688,348
688,348
697,372
705,814
705,814
705,814
705,814
705,814
707,812
781,988
781,988
737,373
737,373
737,373
737,373
432,688
432,688
432,688
386,686
71,976
71,976
72,305
72,305
33,030
33,030
33,030
33,030
33,030
33,030
33,030
33,030
117
117
11711733,03033,03033,03033,03033,03033,03033,03033,03072,30572,30571,97671,976386,686432,688432,688432,688737,373737,373737,373737,373781,988781,988707,812705,814705,814705,814705,814705,814697,372688,348688,348688,348687,416687,850684,042355,941000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
335,359
333,737
343,641
341,298
350,774
342,334
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000342,334350,774341,298343,641333,737335,35900000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
44,193
49,110
46,544
41,435
44,429
40,825
44,198
109,085
0
117,704
116,424
105,440
104,873
103,994
91,755
89,058
2,092
87,376
2,777
91,996
792
95,411
760
100,317
633
84,081
51
83,597
78,048
176,294
289,821
355,533
292,851
351,202
253,766
46,236
2,446
45,545
2,403
45,196
2,466
58,778
2,678
58,260
2,542
57,339
2,324
44,784
4,137
44,089
2,088
40,964
40,543
40,329
385,524
748,931
752,243
751,307
751,800
795,329
777,970
797,026
794,559
793,402
794,367
794,080
793,868
777,854
76,233
75,963
110,664
355,866
375,300
398,779
365,228
380,810
349,191
342,740
244,778
251,097
255,263
256,013
210,441
210,339
209,661
211,101
204,355
232,897
236,709
239,933
168,218
168,911
168,911168,218239,933236,709232,897204,355211,101209,661210,339210,441256,013255,263251,097244,778342,740349,191380,810365,228398,779375,300355,866110,66475,96376,233777,854793,868794,080794,367793,402794,559797,026777,970795,329751,800751,307752,243748,931385,52440,32940,54340,9642,08844,0894,13744,7842,32457,3392,54258,2602,67858,7782,46645,1962,40345,5452,44646,236253,766351,202292,851355,533289,821176,29478,04883,5975184,081633100,31776095,41179291,9962,77787,3762,09289,05891,755103,994104,873105,440116,424117,7040109,08544,19840,82544,42941,43546,54449,11044,193
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,695,917
2,748,496
2,860,744
22,850
22,850
7,850
1,050,093
2,850
0
0
0
10,356
3,988
10,118
10,703
10,825
10,875
10,874
10,855
187,720
189,390
189,390187,72010,85510,87410,87510,82510,70310,1183,98810,3560002,8501,050,0937,85022,85022,8502,860,7442,748,4962,695,91700000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
173,769
197,380
159,890
122,475
200,964
203,397
242,880
343,981
0
350,071
304,230
285,642
317,252
330,806
550,107
523,740
514,871
514,981
510,481
494,832
493,451
464,736
486,076
489,877
463,183
511,162
477,432
502,699
504,156
501,771
650,595
655,131
686,287
657,655
684,136
480,776
487,519
467,882
413,528
417,672
414,775
409,031
420,657
424,643
414,340
423,570
430,288
437,504
438,908
370,379
331,471
355,724
361,000
359,381
919,761
1,016,253
1,045,383
1,086,533
1,194,208
1,631,196
1,555,598
1,528,273
2,521,634
2,403,595
2,665,644
2,628,852
2,268,863
1,963,661
1,998,740
2,232,335
2,365,035
2,294,688
2,360,731
3,043,129
2,408,266
2,435,506
2,134,998
2,129,094
2,051,836
1,960,961
1,811,660
1,822,309
1,464,569
1,348,506
1,342,581
1,299,330
1,253,646
1,251,236
1,240,168
1,247,938
1,214,027
1,248,555
1,248,5551,214,0271,247,9381,240,1681,251,2361,253,6461,299,3301,342,5811,348,5061,464,5691,822,3091,811,6601,960,9612,051,8362,129,0942,134,9982,435,5062,408,2663,043,1292,360,7312,294,6882,365,0352,232,3351,998,7401,963,6612,268,8632,628,8522,665,6442,403,5952,521,6341,528,2731,555,5981,631,1961,194,2081,086,5331,045,3831,016,253919,761359,381361,000355,724331,471370,379438,908437,504430,288423,570414,340424,643420,657409,031414,775417,672413,528467,882487,519480,776684,136657,655686,287655,131650,595501,771504,156502,699477,432511,162463,183489,877486,076464,736493,451494,832510,481514,981514,871523,740550,107330,806317,252285,642304,230350,0710343,981242,880203,397200,964122,475159,890197,380173,769
   > Total Current Liabilities 
125,758
150,585
116,811
98,024
176,515
178,947
218,430
333,980
0
340,072
298,229
279,642
311,252
323,806
533,106
506,740
497,871
497,981
510,481
494,832
493,421
464,706
486,076
486,101
463,183
511,161
471,151
497,998
499,454
497,070
453,959
458,495
489,651
396,218
342,824
331,537
338,279
318,642
294,419
298,563
295,666
289,922
416,479
420,465
410,162
419,392
426,241
433,457
434,928
366,399
327,555
351,807
357,150
355,532
797,850
894,835
808,610
853,346
969,656
1,128,739
983,051
956,220
1,292,671
1,061,029
1,325,369
1,294,212
1,047,425
944,100
972,601
1,069,735
1,383,093
1,148,772
1,280,514
1,812,214
1,668,414
1,725,561
1,468,656
1,545,049
1,858,665
1,778,938
1,650,452
1,673,670
1,361,084
1,251,736
1,176,694
1,138,263
1,083,361
1,082,003
1,072,152
1,080,783
1,041,543
1,078,000
1,078,0001,041,5431,080,7831,072,1521,082,0031,083,3611,138,2631,176,6941,251,7361,361,0841,673,6701,650,4521,778,9381,858,6651,545,0491,468,6561,725,5611,668,4141,812,2141,280,5141,148,7721,383,0931,069,735972,601944,1001,047,4251,294,2121,325,3691,061,0291,292,671956,220983,0511,128,739969,656853,346808,610894,835797,850355,532357,150351,807327,555366,399434,928433,457426,241419,392410,162420,465416,479289,922295,666298,563294,419318,642338,279331,537342,824396,218489,651458,495453,959497,070499,454497,998471,151511,161463,183486,101486,076464,706493,421494,832510,481497,981497,871506,740533,106323,806311,252279,642298,229340,0720333,980218,430178,947176,51598,024116,811150,585125,758
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86,200
86,200
110,490
681,000
746,000
1,203,050
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001,203,050746,000681,000110,49086,20086,20000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86,200
86,200
110,490
681,000
746,000
1,203,050
1,091,050
1,172,050
961,050
905,000
940,000
802,000
794,923
792,473
475,667
422,904
338,104
323,520
213,018
209,118
206,493
199,503
195,823
194,523
194,523195,823199,503206,493209,118213,018323,520338,104422,904475,667792,473794,923802,000940,000905,000961,0501,172,0501,091,0501,203,050746,000681,000110,49086,20086,20000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
12,345
34,594
37,786
46,463
50,389
50,315
59,551
79,217
0
78,197
61,631
47,651
53,915
55,390
110,131
83,745
94,667
66,849
62,826
68,693
64,357
49,699
53,958
54,193
54,453
51,225
45,895
54,934
50,158
51,402
49,863
35,090
41,555
39,739
45,560
55,023
50,677
49,510
50,029
49,006
50,184
40,920
46,395
46,870
50,190
54,120
61,401
55,455
60,067
53,514
58,240
52,818
52,134
48,727
86,710
119,765
127,770
153,641
134,475
150,059
139,078
139,832
111,042
119,406
121,124
140,766
114,239
119,287
127,446
143,234
194,813
165,709
178,368
194,684
187,057
163,984
134,960
136,242
186,249
224,828
151,509
194,023
122,967
125,419
122,590
113,787
138,543
135,688
124,085
112,847
148,936
165,388
165,388148,936112,847124,085135,688138,543113,787122,590125,419122,967194,023151,509224,828186,249136,242134,960163,984187,057194,684178,368165,709194,813143,234127,446119,287114,239140,766121,124119,406111,042139,832139,078150,059134,475153,641127,770119,76586,71048,72752,13452,81858,24053,51460,06755,45561,40154,12050,19046,87046,39540,92050,18449,00650,02949,51050,67755,02345,56039,73941,55535,09049,86351,40250,15854,93445,89551,22554,45354,19353,95849,69964,35768,69362,82666,84994,66783,745110,13155,39053,91547,65161,63178,197079,21759,55150,31550,38946,46337,78634,59412,345
       Other Current Liabilities 
23,413
34,091
32,125
13,931
13,496
15,002
24,249
29,683
0
30,795
50,018
45,411
39,757
50,836
53,395
52,675
35,607
46,398
70,602
57,651
54,956
57,824
73,439
110,789
85,411
162,617
19,837
37,645
61,514
61,449
37,077
52,098
77,414
56,647
71,245
50,495
65,583
73,713
25,390
31,557
32,482
36,002
42,284
45,795
63,902
69,202
68,770
81,932
78,791
16,815
35,745
51,319
53,445
55,235
231,141
233,071
237,390
236,255
318,731
220,868
231,717
242,018
372,268
221,623
359,397
313,446
311,143
220,323
140,202
220,851
250,455
141,017
186,333
244,380
290,627
374,383
257,179
473,957
320,963
744,849
225,077
244,984
366,651
341,040
269,481
348,091
418,903
425,337
336,042
386,517
10,672
9,140
9,14010,672386,517336,042425,337418,903348,091269,481341,040366,651244,984225,077744,849320,963473,957257,179374,383290,627244,380186,333141,017250,455220,851140,202220,323311,143313,446359,397221,623372,268242,018231,717220,868318,731236,255237,390233,071231,14155,23553,44551,31935,74516,81578,79181,93268,77069,20263,90245,79542,28436,00232,48231,55725,39073,71365,58350,49571,24556,64777,41452,09837,07761,44961,51437,64519,837162,61785,411110,78973,43957,82454,95657,65170,60246,39835,60752,67553,39550,83639,75745,41150,01830,795029,68324,24915,00213,49613,93132,12534,09123,413
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,145,916
1,080,217
1,230,915
739,852
709,945
666,342
584,045
193,170
182,023
161,207
148,638
103,485
96,770
165,887
161,067
170,284
169,233
168,016
167,156
172,484
170,555
170,555172,484167,156168,016169,233170,284161,067165,88796,770103,485148,638161,207182,023193,170584,045666,342709,945739,8521,230,9151,080,2171,145,91600000000000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-86,200
-86,200
-110,490
-681,000
-746,000
-1,203,050
0
0
0
0
0
0
0
0
7,874
8,746
9,195
8,977
9,844
10,129
9,845
9,772
22,687
21,755
21,75522,6879,7729,84510,1299,8448,9779,1958,7467,87400000000-1,203,050-746,000-681,000-110,490-86,200-86,20000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
891,840
875,373
875,911
17,468
17,468
17,468
17,468
22,319
22,319
22,319
22,319
38,336
38,336
28,630
28,630
58,928
58,004
58,726
58,726
49,083
49,083
49,08349,08358,72658,72658,00458,92828,63028,63038,33638,33622,31922,31922,31922,31917,46817,46817,46817,468875,911875,373891,84000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
284,886
303,399
347,815
356,671
383,876
392,504
396,173
401,238
380,023
366,884
253,761
256,847
246,195
246,270
117,405
118,522
109,432
112,048
106,916
136,815
142,416
147,345
0
0
00147,345142,416136,815106,916112,048109,432118,522117,405246,270246,195256,847253,761366,884380,023401,238396,173392,504383,876356,671347,815303,399284,88600000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
472,347
490,746
499,583
497,470
499,097
504,648
509,583
511,177
883,002
520,034
525,688
528,308
533,668
519,969
324,966
325,375
326,047
328,021
328,180
329,408
329,914
330,209
334,772
333,355
331,987
332,195
333,829
332,339
331,747
330,261
291,660
277,898
266,772
253,164
53,661
44,265
42,374
32,951
57,294
46,834
38,639
24,606
323
0
0
0
0
0
0
0
4,942
0
0
0
981,188
1,890,978
1,958,284
2,021,767
2,173,660
2,180,739
2,179,108
2,227,684
2,392,194
2,425,354
2,279,188
2,316,978
2,378,469
2,398,945
2,401,950
2,441,159
2,483,665
2,492,938
2,533,723
2,328,291
1,588,007
1,589,552
1,721,506
1,658,660
442,775
473,658
603,843
534,691
306,390
309,728
295,213
276,724
177,928
178,900
165,469
129,344
-49,494
-45,972
-45,972-49,494129,344165,469178,900177,928276,724295,213309,728306,390534,691603,843473,658442,7751,658,6601,721,5061,589,5521,588,0072,328,2912,533,7232,492,9382,483,6652,441,1592,401,9502,398,9452,378,4692,316,9782,279,1882,425,3542,392,1942,227,6842,179,1082,180,7392,173,6602,021,7671,958,2841,890,978981,1880004,942000000032324,60638,63946,83457,29432,95142,37444,26553,661253,164266,772277,898291,660330,261331,747332,339333,829332,195331,987333,355334,772330,209329,914329,408328,180328,021326,047325,375324,966519,969533,668528,308525,688520,034883,002511,177509,583504,648499,097497,470499,583490,746472,347
   Common Stock
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
0
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
280,000
275,425
336,710
336,710
336,710
336,710
336,710
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
416,690
0
0
00416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690416,690336,710336,710336,710336,710336,710275,425280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,000280,0000280,000280,000280,000280,000280,000280,000280,000280,000
   Retained Earnings 
63,800
75,306
84,659
77,883
79,511
85,061
89,997
89,798
0
98,655
101,734
104,354
109,714
95,964
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
488,198
529,923
597,053
660,536
812,300
852,650
851,059
899,514
1,065,986
1,099,178
1,124,689
1,168,954
1,228,072
1,254,803
1,286,189
1,335,981
1,406,087
1,315,437
1,359,275
1,153,298
523,280
524,662
661,834
599,096
-622,491
-594,945
-461,447
-530,575
-708,895
-705,557
-720,357
-738,652
-837,058
-835,779
-849,903
-885,831
-1,177,300
-1,173,795
-1,173,795-1,177,300-885,831-849,903-835,779-837,058-738,652-720,357-705,557-708,895-530,575-461,447-594,945-622,491599,096661,834524,662523,2801,153,2981,359,2751,315,4371,406,0871,335,9811,286,1891,254,8031,228,0721,168,9541,124,6891,099,1781,065,986899,514851,059852,650812,300660,536597,053529,923488,198000000000000000000000000000000000000000095,964109,714104,354101,73498,655089,79889,99785,06179,51177,88384,65975,30663,800
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
320
-27
66
212
379
652
504
668
497
390
1,044
4,381
1,068
1,044
-18,826
-18,826
-18,540
-18,735
-19,456
-19,762
-19,069
-19,267
0
0
00-19,267-19,069-19,762-19,456-18,735-18,540-18,826-18,8261,0441,0684,3811,04439049766850465237921266-2732000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue656,894
Cost of Revenue-185,519
Gross Profit471,375471,375
 
Operating Income (+$)
Gross Profit471,375
Operating Expense-734,287
Operating Income-77,394-262,913
 
Operating Expense (+$)
Research Development52,505
Selling General Administrative439,615
Selling And Marketing Expenses0
Operating Expense734,287492,121
 
Net Interest Income (+$)
Interest Income1,208
Interest Expense-39,932
Other Finance Cost-114
Net Interest Income-38,837
 
Pretax Income (+$)
Operating Income-77,394
Net Interest Income-38,837
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-173,665-77,394
EBIT - interestExpense = -39,932
-215,144
-175,213
Interest Expense39,932
Earnings Before Interest and Taxes (EBIT)0-133,734
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-173,665
Tax Provision-32,835
Net Income From Continuing Ops-206,500-206,500
Net Income-215,144
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net038,837
 

Technical Analysis of Hunan Jingfeng Pharmaceutical
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hunan Jingfeng Pharmaceutical. The general trend of Hunan Jingfeng Pharmaceutical is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hunan Jingfeng Pharmaceutical's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hunan Jingfeng Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.25 < 1.48 < 1.51.

The bearish price targets are: .

Tweet this
Hunan Jingfeng Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hunan Jingfeng Pharmaceutical. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hunan Jingfeng Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hunan Jingfeng Pharmaceutical. The current macd is -0.23048047.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hunan Jingfeng Pharmaceutical price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hunan Jingfeng Pharmaceutical. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hunan Jingfeng Pharmaceutical price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hunan Jingfeng Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartHunan Jingfeng Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hunan Jingfeng Pharmaceutical. The current adx is 48.43.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Hunan Jingfeng Pharmaceutical shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Hunan Jingfeng Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hunan Jingfeng Pharmaceutical. The current sar is 1.03138035.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hunan Jingfeng Pharmaceutical Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hunan Jingfeng Pharmaceutical. The current rsi is 18.06. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Hunan Jingfeng Pharmaceutical Daily Relative Strength Index (RSI) ChartHunan Jingfeng Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hunan Jingfeng Pharmaceutical. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hunan Jingfeng Pharmaceutical price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Hunan Jingfeng Pharmaceutical Daily Stochastic Oscillator ChartHunan Jingfeng Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hunan Jingfeng Pharmaceutical. The current cci is -125.80389829.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Hunan Jingfeng Pharmaceutical Daily Commodity Channel Index (CCI) ChartHunan Jingfeng Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hunan Jingfeng Pharmaceutical. The current cmo is -78.61596859.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hunan Jingfeng Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartHunan Jingfeng Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hunan Jingfeng Pharmaceutical. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Hunan Jingfeng Pharmaceutical Daily Williams %R ChartHunan Jingfeng Pharmaceutical Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hunan Jingfeng Pharmaceutical.

Hunan Jingfeng Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hunan Jingfeng Pharmaceutical. The current atr is 0.07984431.

Hunan Jingfeng Pharmaceutical Daily Average True Range (ATR) ChartHunan Jingfeng Pharmaceutical Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hunan Jingfeng Pharmaceutical. The current obv is 225,137,952.

Hunan Jingfeng Pharmaceutical Daily On-Balance Volume (OBV) ChartHunan Jingfeng Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hunan Jingfeng Pharmaceutical. The current mfi is 26.81.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hunan Jingfeng Pharmaceutical Daily Money Flow Index (MFI) ChartHunan Jingfeng Pharmaceutical Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hunan Jingfeng Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-05-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Hunan Jingfeng Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hunan Jingfeng Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5018.062
Ma 20Greater thanMa 501.230
Ma 50Greater thanMa 1001.533
Ma 100Greater thanMa 2001.889
OpenGreater thanClose0.800
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hunan Jingfeng Pharmaceutical with someone you think should read this too:
  • Are you bullish or bearish on Hunan Jingfeng Pharmaceutical? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hunan Jingfeng Pharmaceutical? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hunan Jingfeng Pharmaceutical

I send you an email if I find something interesting about Hunan Jingfeng Pharmaceutical.


Stay informed about Hunan Jingfeng Pharmaceutical.

Receive notifications about Hunan Jingfeng Pharmaceutical in your mailbox!